Abstract
Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Current Drug Delivery
Title: Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Volume: 8 Issue: 1
Author(s): Hong Song and George Sgouros
Affiliation:
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Abstract: Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Export Options
About this article
Cite this article as:
Song Hong and Sgouros George, Radioimmunotherapy of Solid Tumors: Searching for the Right Target, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663651
DOI https://dx.doi.org/10.2174/156720111793663651 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Reviews on Recent Clinical Trials Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Current Signal Transduction Therapy Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions
Current Topics in Medicinal Chemistry Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Phosphoproteomics: Challenges and Opportunities
Current Proteomics State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters In Utero Gene Therapy: Prospect and Future
Current Pharmaceutical Design Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science